Top Commitment
"Creating Social Value Through ESG as We Become a Total Healthcare Company"
President, Representative Director
The promotion of ESG management is a key measure in Medium-Term Management Plan 2025 and integral to our corporate philosophy of “Contribute toward the improvement of people’s health and progress in society through the development of innovative products.” When we adopted the holdings structure in 2021, we also established the ESG Committee. Since then, the committee has been the impetus in identifying and analyzing material issues that should be taken up by the entire Group. In addition, the committee is striving to practice corporate philosophy, enhance corporate value over the medium to long term, and to construct relationships of trust with all our stakeholders.
We have set specific numerical targets related to the environment (the E in ESG). These include targets related to our measures to address climate change and to reduce CO2 emissions by expanding solar power equipment and introducing clean energy, as we work to realize eco-friendly business management.
In terms of society (S), we intend to continue the unique activities of each of our businesses based on their particular approach of contributing to society, such as contributing to people’s health and enhancing their quality of life. One of the Group’s major social missions is to support the healthy lives of women throughout each life stage by leveraging the information communication capabilities of Health Lab Mint+ for Women’s Health, which we established in 2020. In addition, in the animal health field, we will advance animal health and food safety as we work to create a society where people and animals can coexist in harmony.
In terms of governance (G), we upgraded the Groupwide governance structure to manage our businesses in line with a unified policy. Recently, we have been working to create workplaces where everyone can thrive, with a focus on hiring and training that emphasizes diversity, to enable the effective collaboration of human resources spanning a wide range of nationalities and cultural backgrounds.
The Group will not only seek to maximize economic value through our business, but also strive to enhance social value as we continue living up to the expectations of our shareholders. We appreciate the continued understanding and support of all our stakeholders.
Sohta Yamaguchi
President, Representative Director
(As of June 24, 2025)
We aim to build a society where women can play a more prominent role and improve animal welfare
My mission as a Board Member in charge of sustainability is to contribute to the resolution of social issues and the building of a sustainable society, while continuously enhancing corporate value by using the knowledge and expertise on hormones that we have accumulated over the past 100 years as a source of growth.
In April 2021, we took a new step forward with the transition to a holding company structure, and we strive to solve social issues through our business based on our corporate philosophy: Contribute toward the improvement of people's health and progress in society through the development of innovative products. The ESG Committee, which was established at the same time as the transition to the holding company structure, has identified 17* material issues that should be promoted throughout the Group, and has been working on the promotion of ESG management.
Firstly, with regard to measures to address climate change, we have disclosed climate-related information in line with the TCFD recommendations, and we have prioritized measures to reduce CO2 emissions by expanding solar power generation and introducing clean energy, especially at our factory that consumes large amounts of energy.
Furthermore, we have set forth in the Medium-Term Management Plan 2025 our management vision: Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company. Among the 17* material issues identified by the ESG Committee, we recognize that "contribution to women's health" and "contribution to animal health" are our characteristic material issues, and we will enhance our corporate value by addressing these material issues on a Group-wide basis.
We firmly believe that the promotion of women's advancement, which is being promoted on a national scale, is closely related to women's health and that this is an area in which we can make a significant contribution, given our materiality of “contribution to women's health.” In addition to expanding our product lineup to solve women's health issues, we will contribute to improving women's health and health literacy by disseminating information from Health Lab Mint⁺ for Women’s health, established in 2020. Furthermore, in April 2023, we began new initiatives, including the establishment of the Femtech Business Promotion Unit to find solutions to a wide range of women's health issues, as well as our existing efforts.
In the area of “contribution to animal health,” we will expand companion animal-related pharmaceuticals and move into the field of veterinary pharmaceuticals for industrial use by leveraging the synergies of the Group based on our knowledge and expertise in hormones.
In April 2023, we newly established the Sustainability Promotion Section within the Corporate Planning Department to further accelerate our efforts to date. We will continue to place sustainability at the center of our management and meet the expectations of our stakeholders by maximizing corporate economic value and enhancing social value at the same time. We look forward to your continued understanding and support.
Atsushi Maruo
In Charge of Sustainability
Senior Managing Member of the Board of Directors, Representative Director
(As of April 3, 2023)
*The number of material issues has now been consolidated to 11.